Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K (Impact Factor: 9.38). 08/2009; 23(11):2147-52. DOI: 10.1038/leu.2009.147
Source: PubMed

ABSTRACT We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethasone plus placebo in patients with relapsed/refractory multiple myeloma (MM). Patients in both studies were randomized to receive 25 mg daily oral lenalidomide or identical placebo, plus 40 mg oral dexamethasone. In this pooled analysis, using data up to unblinding (June 2005 for MM-009 and August 2005 for MM-010), treatment with lenalidomide plus dexamethasone significantly improved overall response (60.6 vs 21.9%, P<0.001), complete response rate (15.0 vs 2.0%, P<0.001), time to progression (median of 13.4 vs 4.6 months, P<0.001) and duration of response (median of 15.8 months vs 7 months, P<0.001) compared with dexamethasone-placebo. At a median follow-up of 48 months for surviving patients, using data up to July 2008, a significant benefit in overall survival (median of 38.0 vs 31.6 months, P=0.045) was retained despite 47.6% of patients who were randomized to dexamethasone-placebo receiving lenalidomide-based treatment after disease progression or study unblinding. Low beta(2)-microglobulin and low bone marrow plasmacytosis were associated with longer survival. In conclusion, these data confirm the significant response and survival benefit with lenalidomide and dexamethasone.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Bone disease is present in the majority of patients with multiple myeloma and can seriously affect quality of life and survival rate. In addition to suppression of osteoclastogenesis, there have been developments made in terms of the therapeutic agents available, such as novel immunomodulating agents, proteasome and receptor activator of nuclear factor κB ligand inhibitors. Areas covered: Areas covered include in vitro, in vivo and clinical evidence was collected using MEDLINE® (1950 - May 2014), EMBASE (1980 - May 2014) and Google Scholar (1980 - May 2014) databases. Expert opinion: Bisphosphonates are the mainstay of myeloma bone disease treatment. Oral clodronate and intravenous pamidronate and zoledronic acid are currently used drugs and seem to have comparable results in preventing skeletal-related events of the disease. Zoledronate can also have survival benefits and based on the available evidence is the superior bisphosphonate; however, its side effects have to be monitored. Denosumab had comparable results with zoledronate on myeloma bone disease treatment; its use has not been completely proven yet. There is an expanding set of drugs, proteasome inhibitors, under investigation with great potential to reduce the negative effects of myeloma cells on bone. Future clinical studies should compare both the catabolic and anabolic effects of these agents on bone.
    Expert Opinion on Biological Therapy 11/2014; 15(2):1-18. DOI:10.1517/14712598.2015.978853 · 3.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is the third most common hematologic malignancy in Korea. Historically, the incidence of MM in Korea has been lower than that in Western populations, although there is growing evidence that the incidence of MM in Asian populations, including Korea, is increasing rapidly. Despite advances in the management of MM, patients will ultimately relapse or become refractory to their current treatment, and alternative therapeutic options are required in the relapsed/refractory setting. In Korea, although lenalidomide/dexamethasone is indicated for the treatment of relapsed or refractory MM (RRMM) in patients who have received at least one prior therapy, lenalidomide is reimbursable specifically only in patients with RRMM who have failed bortezomib-based treatment. Based on evidence from pivotal multinational clinical trials as well as recent studies in Asia, including Korea, lenalidomide/dexamethasone is an effective treatment option for patients with RRMM, regardless of age or disease status. Adverse events associated with lenalidomide/dexamethasone, including hematologic toxicity, venous thromboembolism, fatigue, rash, infection, and muscle cramps, are largely predictable and preventable/manageable with appropriate patient monitoring and/or the use of standard supportive medication and dose adjustment/interruption. Lenalidomide/dexamethasone provides an optimal response when used at first relapse, and treatment should be continued long term until disease progression. With appropriate modification of the lenalidomide starting dose, lenalidomide/dexamethasone is effective in patients with renal impairment and/or cytopenia. This review presents updated evidence from the published clinical literature and provides recommendations from an expert panel of Korean physicians regarding the use of lenalidomide/dexamethasone in patients with RRMM.
    03/2015; 50(1):7-18. DOI:10.5045/br.2015.50.1.7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic options for patients with multiple myeloma (MM) whose disease has relapsed after a prior autologous stem cell transplant (ASCT) include an expanding armamentarium of novel agents, often combined with traditional chemotherapy, or a second ASCT, with no clear standard of care. We retrospectively analyzed the outcomes of 75 patients who underwent salvage melphalan-based ASCT for relapsed MM at Memorial Sloan-Kettering Cancer Center. between 1995 and 2012. Conditioning was with melphalan 200mg/m2 (N=43), 180mg/m2 (N=1), 140mg/m2 (N=22), 100mg/m2 (N=9). The median age at 2(nd) SCT was 59 years (range 36-75) and 58% (N=35) were male. Of those with available data, 19% had high risk cytogenetics (including t (4;14), p53 loss or del 13q by karyotype) at the time of second ASCT. Median interval between first and salvage ASCT was 37.5 months (range 6.9 -111.4). Of 72 evaluable patients, 57% had chemotherapy sensitive disease prior to salvage SCT and 43% were chemoresistant. Four patients died within 100 days of ASCT. Response was assessed at 2-3 mos post-SCT and of 71 evaluable patients, 82% achieved >= partial response, 15% had stable disease and 3% progressed despite salvage SCT. Following salvage SCT, 38 patients received maintenance therapy and 14 went on to allogeneic SCT. The median PFS following second autograft was 10.1 mos (95% CI: 7.6-13.4); the median OS was 22.7 mos (95% CI: 19.2 - 41.2). Patients with chemosensitive relapse had a trend toward better progression free survival (HR-0.60 (95% CI: 0.36- 1.02) P = 0.058) and significantly longer overall survival (HR 0.49 (95% CI: 0.27 0.88), P = 0.017) than patients with resistant relapse. Those with high-risk cytogenetics at the time of second ASCT had higher risk of death (HR 2.98 (95% CI: 1.28- 6.97), P = 0.012) compared to patients with standard risk cytogenetics. Salvage ASCT is an effective strategy for relapsed MM with chemosensitive disease and results in comparable PFS and OS to other salvage strategies. Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 12/2014; 21(3). DOI:10.1016/j.bbmt.2014.11.677 · 3.35 Impact Factor